The Interleukin 17A pipeline drugs market research report outlays comprehensive information on the Interleukin 17A targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Interleukin 17A pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Immunology, Musculoskeletal Disorders, Dermatology, and Ophthalmology which include the indications Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Ankylosing Spondylitis (Bekhterev’s Disease), Psoriatic Arthritis, Hidradenitis Suppurativa, Unspecified Dermatological Disorders, Uveitis, and Graves’ Ophthalmopathy. It also reviews key players involved in Interleukin 17A targeted therapeutics development with respective active and dormant or discontinued products.
The Interleukin 17A pipeline targets constitutes close to 38 molecules. Out of which, approximately 36 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 2, 11, 2, 4, 4, 8, and 5 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Interleukin 17A overview
Interleukin 17A (IL-17A) is a effector cytokine of the innate and adaptive immune systems involved in antimicrobial host defense and maintenance of tissue integrity. It signals via the IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways, ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation.
For a complete picture of Interleukin 17A’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.